Table 4 Subgroup analysis of PFS of patients treated with metronomic vs. conventional zoledronic acid
Clinical and biochemical factor | HR (95% CI) | P | |
|---|---|---|---|
DFI (year) | > 2 | 1.318 (0.660-2.630) | 0.437 |
|  | ≤ 2 | 3.455 (1.043-11.445) | 0.043 |
ER status | + | 1.036 (0.504-2.130) | 0.922 |
| Â | - | 4.178 (1.130-15.450) | 0.032 |
Lymph node status | ≤ 3 | 1.340 (0.699-2.568) | 0.378 |
| Â | > 3 | 2.093 (0.636-6.893) | 0.224 |
Numbers of previous chemotherapy | ≤ 2 | 1.107 (0.586-2.093) | 0.754 |
| Â | > 2 | 11.440 (1.348-97.069) | 0.025 |
Baseline CEA (ug/L) | ≤ 10 | 1.281 (0.644-2.549) | 0.481 |
| Â | > 10 | 3.927 (1.179-13.079) | 0.026 |
Baseline CA 15-3 (U/mL) | ≤ 25 | 0.762 (0.258-2.251) | 0.623 |
| Â | > 25 | 2.087 (1.056-4.122) | 0.034 |
Baseline NTx (nM BCE) | ≤ 18 | 0.945 (0.399-2.241) | 0.898 |
| Â | > 18 | 2.520 (1.141-5.566) | 0.022 |
Baseline VEGF (pg/mL) | ≤ 500 | 2.337 (0.522-10.468) | 0.267 |
| Â | > 500 | 1.186 (0.546-2.573) | 0.667 |
VEGF (3 months after intervention) (pg/mL) | ≤ 500 | 0.834 (0.340-2.046) | 0.692 |
| Â | > 500 | 1.596 (0.619-4.115) | 0.333 |